Carna Biosciences, Inc. (4572.T)
JPY 280.0
(-1.41%)
JPY 280.0
(-1.41%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.34 Billion JPY | 1.96% |
| 2022 | 4.26 Billion JPY | -21.47% |
| 2021 | 5.43 Billion JPY | 12.35% |
| 2020 | 4.83 Billion JPY | -10.07% |
| 2019 | 5.37 Billion JPY | 203.75% |
| 2018 | 1.77 Billion JPY | -19.19% |
| 2017 | 2.19 Billion JPY | -14.65% |
| 2016 | 2.56 Billion JPY | 9.78% |
| 2015 | 2.33 Billion JPY | 91.38% |
| 2014 | 1.22 Billion JPY | -35.34% |
| 2013 | 1.88 Billion JPY | 69.13% |
| 2012 | 1.11 Billion JPY | -15.23% |
| 2011 | 1.31 Billion JPY | -20.44% |
| 2010 | 1.65 Billion JPY | -18.97% |
| 2009 | 2.04 Billion JPY | -1.3% |
| 2008 | 2.07 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.68 Billion JPY | -5.36% |
| 2024 Q1 | 3.89 Billion JPY | -10.48% |
| 2023 Q4 | 4.34 Billion JPY | 3.76% |
| 2023 Q2 | 4.56 Billion JPY | -7.69% |
| 2023 FY | 4.34 Billion JPY | 1.96% |
| 2023 Q3 | 4.19 Billion JPY | -8.17% |
| 2023 Q1 | 4.94 Billion JPY | 15.91% |
| 2022 Q3 | 4.54 Billion JPY | -12.85% |
| 2022 Q2 | 5.21 Billion JPY | -2.56% |
| 2022 Q1 | 5.35 Billion JPY | -1.42% |
| 2022 FY | 4.26 Billion JPY | -21.47% |
| 2022 Q4 | 4.26 Billion JPY | -6.19% |
| 2021 Q3 | 4.21 Billion JPY | 14.99% |
| 2021 Q2 | 3.66 Billion JPY | -13.38% |
| 2021 Q1 | 4.22 Billion JPY | -12.56% |
| 2021 Q4 | 5.43 Billion JPY | 29.0% |
| 2021 FY | 5.43 Billion JPY | 12.35% |
| 2020 Q2 | 5.34 Billion JPY | -5.24% |
| 2020 Q1 | 5.64 Billion JPY | 4.98% |
| 2020 FY | 4.83 Billion JPY | -10.07% |
| 2020 Q4 | 4.83 Billion JPY | -7.51% |
| 2020 Q3 | 5.22 Billion JPY | -2.27% |
| 2019 FY | 5.37 Billion JPY | 203.75% |
| 2019 Q1 | 1.6 Billion JPY | -9.55% |
| 2019 Q2 | 3.9 Billion JPY | 143.67% |
| 2019 Q3 | 5.12 Billion JPY | 31.46% |
| 2019 Q4 | 5.37 Billion JPY | 4.84% |
| 2018 Q3 | 1.62 Billion JPY | -16.84% |
| 2018 Q4 | 1.77 Billion JPY | 8.65% |
| 2018 Q2 | 1.95 Billion JPY | -12.02% |
| 2018 FY | 1.77 Billion JPY | -19.19% |
| 2018 Q1 | 2.22 Billion JPY | 1.66% |
| 2017 Q3 | 2.27 Billion JPY | 3.78% |
| 2017 FY | 2.19 Billion JPY | -14.65% |
| 2017 Q4 | 2.19 Billion JPY | -3.77% |
| 2017 Q2 | 2.19 Billion JPY | -9.05% |
| 2017 Q1 | 2.41 Billion JPY | -6.03% |
| 2016 Q1 | 2.29 Billion JPY | -1.71% |
| 2016 FY | 2.56 Billion JPY | 9.78% |
| 2016 Q4 | 2.56 Billion JPY | -3.47% |
| 2016 Q3 | 2.65 Billion JPY | 1.12% |
| 2016 Q2 | 2.62 Billion JPY | 14.43% |
| 2015 Q2 | 2.49 Billion JPY | 99.63% |
| 2015 Q1 | 1.25 Billion JPY | 2.35% |
| 2015 FY | 2.33 Billion JPY | 91.38% |
| 2015 Q4 | 2.33 Billion JPY | -1.34% |
| 2015 Q3 | 2.36 Billion JPY | -5.06% |
| 2014 FY | 1.22 Billion JPY | -35.34% |
| 2014 Q4 | 1.22 Billion JPY | -25.87% |
| 2014 Q3 | 1.64 Billion JPY | -2.26% |
| 2014 Q2 | 1.68 Billion JPY | -6.12% |
| 2014 Q1 | 1.79 Billion JPY | -4.94% |
| 2013 FY | 1.88 Billion JPY | 69.13% |
| 2013 Q1 | 1.13 Billion JPY | 1.3% |
| 2013 Q2 | 1.15 Billion JPY | 2.17% |
| 2013 Q3 | 1.66 Billion JPY | 44.24% |
| 2013 Q4 | 1.88 Billion JPY | 13.29% |
| 2012 FY | 1.11 Billion JPY | -15.23% |
| 2012 Q2 | 1.05 Billion JPY | -14.1% |
| 2012 Q3 | 903.07 Million JPY | -14.14% |
| 2012 Q4 | 1.11 Billion JPY | 23.68% |
| 2012 Q1 | 1.22 Billion JPY | -7.06% |
| 2011 FY | 1.31 Billion JPY | -20.44% |
| 2011 Q4 | 1.31 Billion JPY | -6.02% |
| 2011 Q1 | 1.57 Billion JPY | -4.74% |
| 2011 Q3 | 1.4 Billion JPY | -5.12% |
| 2011 Q2 | 1.47 Billion JPY | -6.34% |
| 2010 Q1 | 2 Billion JPY | -1.97% |
| 2010 Q2 | 1.86 Billion JPY | -7.09% |
| 2010 Q4 | 1.65 Billion JPY | -5.02% |
| 2010 FY | 1.65 Billion JPY | -18.97% |
| 2010 Q3 | 1.74 Billion JPY | -6.32% |
| 2009 Q4 | 2.04 Billion JPY | 13.42% |
| 2009 Q3 | 1.8 Billion JPY | 1.17% |
| 2009 Q2 | 1.78 Billion JPY | -5.76% |
| 2009 Q1 | 1.89 Billion JPY | 0.0% |
| 2009 FY | 2.04 Billion JPY | -1.3% |
| 2008 FY | 2.07 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 33.986% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -259.072% |
| GNI Group Ltd. | 62.39 Billion JPY | 93.028% |
| Linical Co., Ltd. | 18.53 Billion JPY | 76.538% |
| Trans Genic Inc. | 9.81 Billion JPY | 55.663% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 22.794% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 37.377% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 25.212% |
| AnGes, Inc. | 28.89 Billion JPY | 84.945% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -401.558% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 97.233% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -168.747% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 14.225% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -78.798% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -83.279% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 37.234% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -148.359% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 14.466% |
| PeptiDream Inc. | 67.12 Billion JPY | 93.52% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -113.167% |
| Ribomic Inc. | 3.54 Billion JPY | -22.627% |
| SanBio Company Limited | 5.04 Billion JPY | 13.817% |
| Healios K.K. | 15.15 Billion JPY | 71.297% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -253.576% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -44.227% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -195.077% |
| StemRIM | 9.08 Billion JPY | 52.094% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 36.772% |
| FunPep Company Limited | 2.49 Billion JPY | -74.615% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -66.112% |
| Stella Pharma Corporation | 3.82 Billion JPY | -13.853% |
| TMS Co., Ltd. | 3.55 Billion JPY | -22.368% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 24.729% |
| Cuorips Inc. | 6.18 Billion JPY | 29.667% |
| K Pharma,Inc. | 3.31 Billion JPY | -31.262% |
| Takara Bio Inc. | 123.2 Billion JPY | 96.469% |
| ReproCELL Incorporated | 9.05 Billion JPY | 51.949% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -60.198% |
| StemCell Institute Inc. | 6.54 Billion JPY | 33.519% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 37.759% |
| CellSeed Inc. | 2.46 Billion JPY | -76.411% |